Macrolide Antibiotics Market Research, 2032
The global macrolide antibiotics market was valued at $5.6 billion in 2022, and is projected to reach $7.0 billion by 2032, growing at a CAGR of 2.3% from 2023 to 2032. Growth of the macrolide antibiotic market is driven by a rise in incidences of bacterial infections around the globe and surge in prescription of macrolide antibiotics for the treatment of these infections.
Macrolides is the class of antibiotics with a macrocyclic lactone structure, to which one or more deoxy sugars are attached. The macrolides inhibit the translocation phases of protein synthesis by binding irreversibly to a spot on the bacterial ribosome's 50S subunit. Although they are typically regarded as bacteriostatic, higher doses might acts as bactericidal drugs. These macrolide antibiotics are used to treat respiratory tract infections such as pneumonia, bronchitis, sinusitis, pharyngitis, and sexually transmitted infections such as chlamydia, gonorrhea, and others.
Market Dynamics
Rise in incidences of infectious diseases around the globe is the major driver for the market growth. According to the National Center for Biotechnology Information (NCBI), the estimated global incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person annually. In addition, the annual incidence in the U.S. is 24.8 cases per 10,000 adults with higher rates as age increases. Rise in prevalence of community-acquired pneumonia in the U.S. and other countries around the globe, increases the demand for macrolide antibiotics for treatment. This propels the growth of the macrolide antibiotics market share.
In addition, other bacterial infections such as Bronchitis, Sinusitis, Pharyngitis, Cellulitis, Impetigo, Erysipelas, and others are on the rise, which further contributes to the increase in macrolide demand and the growth of the global macrolide antibiotics market size.
Furthermore, availability of generic antibiotics is also expanding the market growth. A large number of players in the market are focused on developing generic versions of branded macrolide antibiotics. This allows the patient to choose from a wide range of generic and branded products, which further contribute to the revenue generation of the market. For instance, Teva Pharmaceuticals offers generic products such as Azithromycin for Oral Suspension, USP and Azithromycin Tablets, and USP. These medications are available at low cost and are easily accessible in all regions around the globe. This fosters the macrolide antibiotics market growth.
However, side effects associated with the excessive use of macrolide antibiotics may act as a restraint to the market growth. Macrolide antibiotics may lead to side effects such as nausea, vomiting, abdominal pain, and diarrhea. It may also include rare side effects such as cardiac arrhythmias and abnormal liver function.
In addition, excessive misuse of macrolide antibiotics may lead to development of macrolide resistance among the species. This makes the macrolide drug ineffective against the pathogen, thereby affecting the treatment process. Rise in antimicrobial resistance may lead to increased healthcare costs, longer hospital stays, and severe infections requiring advanced treatment, which is expected to hamper the adoption of macrolide antibiotics and hinder the growth of macrolide antibiotics market size.
However, to overcome this burden of antimicrobial resistance, companies are investing in R&D to innovate and launch new and novel macrolide antibiotics, which can act on these resistant bacteria. Rise in antimicrobial resistance among the pathogen increases the demand for novel macrolide antibiotics, which is anticipated to drive the market growth during the macrolide antibiotics market forecast period.
The ongoing global economic recession influences several industries, including biotechnology and pharmaceuticals, which has an impact on the development and demand for antibiotics such as macrolides. The demand for antibiotics has fluctuated as a result of funding cuts in the pharmaceutical, biotechnology, and chemical industries, and the discovery of new macrolide antibiotics has been hampered by reduced research funding. In addition, small and mid-sized pharmaceutical companies are particularly affected by the economic crisis, which delays capital-raising plans and causes supply chain interruptions that hinder output.
Despite these challenges, the macrolide antibiotics market continues to experience moderate revenue growth due to the ongoing need for antibiotics in healthcare. The demand for macrolide antibiotics has remained comparatively consistent throughout the recession as the market participants are adjusting manufacturing capabilities and concentrating on the usage of current inventory.
Segmental Overview
The macrolide antibiotics industry is segmented on the basis of drug type, route of administration, indication, distribution channel, and region. By drug type, the market is classified into azithromycin, erythromycin, and others. By route of administration, the market is segmented into oral, parenteral, and topical. By indication, the market is segmented into respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, and others. By distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By Drug Type
On the basis of drug type, the azithromycin segment dominated the global market in 2022. The growth is mainly attributed to the application of azithromycin in the treatment of various bacterial infections. Azithromycin is the first line treatment for cholera, enteric fever, gonorrhea, sexually transmitted infection due to chlamydia trachomatis, trachoma and yaws. In addition, it is a second choice of drug for the treatment of acute invasive bacterial diarrhea or dysentery. As the incidences of these bacterial infections are on the rise, the demand for azithromycin for treatment also increases. Thus, contributing to the macrolide antibiotics market share .
On the other hand, the others segment is anticipated to be the fastest growing segment during the forecast period. This growth is mainly due to the product approvals for the products belonging to the others segment, which will boost the market share in coming years.
By Route of Administration
By route of administration, the oral segment dominated the global market in 2022 and is anticipated to be the fastest growing segment during the forecast period. The growth of the oral segment is mainly attributed to the wide availability of macrolide tablets in the market in branded as well as generic form. This wide availability of oral products increases its adoption in the market and thus, contributes to the segment growth. In addition, advantages offered by oral dosage form such as easy administration, less side effects, easy accessibility, and low cost of oral generic macrolides also increase its adoption in the market. Thus, further propelling the segment growth.
By Indication
By indication, the respiratory tract infections dominated the market in terms of revenue in 2022 and is anticipated to be the fastest growing segment during the forecast period. The growth of the segment is attributed to the high prevalence of respiratory tract infections such as pneumonia, bronchitis, sinusitis and pharyngitis. Also, these infections are on the rise in the lower- and middle-income countries, which increases the demand for macrolide antibiotics for treatment, thereby boosting the segment growth.
By Distribution Channel
By distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2022, owing to the easy accessibilty of medications as these channels are available in the locality of the patients and patients can access medications at any time whenever needed. On other hand, the online providers segment is anticipated to be the fastest growing segment during the forecast period, which is attributed to the advantages such as cost effectiveness, door step delivery and others that are offered by online providers.
By Region
The macrolide antibiotics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific region dominated the market in terms of revenue in 2022 and is anticipated to be the fastest growing segment during the forecast period. The growth in this region is mainly attributed to the huge population base and high prevalence of bacterial infections in this region. Developing countries have insufficient sanitation and poor hygiene practices can contribute to the spread of bacterial infections, which increases the demand for macrolide antibiotics for the treatment.
In addition, the presence of several major players, such as Pfizer Inc, Alkem Laboratories Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Limited contributes to the market growth in the region. In addition, countries such as India and China have major operations for pharmaceutical manufacturing and are the major exporters for antibiotic including macrolide antibiotics around the globe. This further contributes to the market expansion.
Competition Analysis
Competition analysis and profiles of the major players in the macrolide antibiotics industry, such as Abbott Laboratories, Pfizer Inc., Alkem Laboratories Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Centurion Healthcare Private Limited, Wellona Pharma, Bristol Laboratories Ltd., and Crescent Pharma Limited. Other key players in the market include Reliance Health Care Pvt. Ltd., Elisa Biotech Pvt. Ltd., Anant Pharmaceuticals Pvt. Ltd., Marc Laboratories Pvt Ltd, Ace Kinetics Health Care Private Limited, Orion Biotech Pvt. Ltd., and others. Major players have adopted product launch and product approval as a key developmental strategy to improve the product portfolio and gain a strong foothold in the macrolide antibiotics market.
Recent Product Launch in the Macrolide Antibiotics Market
- In May 2021, Teva Pharmaceuticals announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets. This drug is a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals and is indicated to treat a variety of bacterial infections, and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin.
Recent Product Approvals in the Macrolide Antibiotics Market
- In March 2023, Zydus Lifesciences Limited received approval from the U.S. Food and Drug Administration (U.S. FDA) for Erythromycin Tablets USP, 250 mg and 500 mg. The drug is indicated for treatment of infections in different parts of the body, including respiratory tract infections, skin infections, diphtheria, intestinal amebiasis, acute pelvic inflammatory disease, legionnaire's disease, pertussis, and syphilis.
- In April 2023, Zydus Lifesciences Limited received approval from the U.S. Food and Drug Administration (U.S. FDA) for Azithromycin Tablets USP, 500 mg. The drug is indicated for treatment of certain bacterial infections such as bronchitis, pneumonia, sexually transmitted diseases (STD), infections of the ears, lungs, sinuses, skin, throat, and reproductive organs.
- In January 2020, Merck announced the U.S. Food and Drug Administration (FDA) approval for a New Drug Application (NDA) for DIFICID (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides difficile-associated diarrhea in children aged six months and older.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the macrolide antibiotics market analysis from 2022 to 2032 to identify the prevailing macrolide antibiotics market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the macrolide antibiotics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global macrolide antibiotics market trends, key players, market segments, application areas, and market growth strategies.
Macrolide Antibiotics Market Report Highlights
| Aspects | Details |
 Market Size By 2032 | USD 7 billion |
 Growth Rate | CAGR of 2.3% |
 Forecast period | 2022 - 2032 |
 Report Pages | 306 |
 By Drug Type |
|
 By Route of Administration |
|
 By Indication |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Abbott Laboratories, Wellona Pharma Private Limited., Merck & Co., Inc., Zydus Lifesciences Limited, Alkem Laboratories Ltd., Pfizer Inc., Bristol Laboratories Ltd., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Crescent Pharma Limited |
Analyst Review
The global macrolide antibiotics market presents several opportunities and challenges. The increasing prevalence of bacterial infections globally remains a key driver for the growth of the macrolide antibiotics market. The demand for effective antibiotics such as azithromycin and erythromycin continue to rise, providing opportunities for market expansion.
In addition, the expanding global population, particularly the aging demographics, contributes to the rise in demand for antibiotic drugs, as the susceptibility to infections increases. Moreover, advancements in drug formulation, manufacturing, and delivery systems enable improved accessibility and convenience, is contributing to the market expansion. In addition, improved healthcare infrastructure, especially in developing regions, enhances access to diagnosis and treatment, thus contributing to the growing demand for macrolides.
Furthermore, Asia-Pacific is anticipated to witness notable growth during the forecast period, owing to rise in investments for R&D in macrolide medications in this region, large population base, and growing access to healthcare services.
The base year is 2022 in macrolide antibiotics market.
The forecast period for macrolide antibiotics market is 2023 to 2032.
The market value of macrolide antibiotics market in 2032 is $7.0 billion.
The total market value of macrolide antibiotics market is $5.6 billion in 2022.
Major players that operate in the macrolide antibiotics market are Abbott Laboratories, Pfizer Inc., Alkem Laboratories Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Centurion Healthcare Private Limited, Wellona Pharma, Bristol Laboratories Ltd., and Crescent Pharma Limited.
The Azithromycin segment is the most influencing segment in the market owing to the significant number of prescriptions of azithromycin by the healthcare professionals.
Key factors driving the growth of the macrolide antibiotics market includes rise in incidences of bacterial infections, availability of generic medications and significant demand for macrolides from emerging countries.
Asia-Pacific has the highest growth rate in the market with 2.8% CAGR owing to highest usage of antibiotics and huge incidences of microbial infections in this region.
Loading Table Of Content...
Loading Research Methodology...
